Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Tranexamic Acid in Hip Fractures
NCT02908516Phase 4Terminated
- Sponsor
- Yale University
- Start
- Sep 2017
- Primary completion
- Nov 2017
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tranexamic acid in hip fracture, sponsored by Yale University. Primary endpoints: Total Blood Loss at 3 days and Change in Hemoglobin Level at 3 days. Started Sep 2017; status: terminated.
02
Drugs
tranexamic acid
03
Conditions
hip fracture
Beyond the preview
Go deeper on NCT02908516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02908516.